Gilead signs deals with Indian cos for low-cost HIV drug
Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug, Emtricitabine in developing countries.
Like this story, share it with millions of investors on M3
Gilead signs deals with Indian cos for low-cost HIV drug
Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug, Emtricitabine in developing countries.
Like this story, share it with millions of investors on M3
Gilead signs deals with Indian cos for low-cost HIV drug
Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug, Emtricitabine in developing countries.
Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug, Emtricitabine in developing countries.
Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.
Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.
